-
1
-
-
0028055214
-
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer
-
North Central Cancer Treatment Group
-
Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 1994; 12: 412-416
-
(1994)
J Clin Oncol
, vol.12
, pp. 412-416
-
-
Cullinan, S.A.1
Moertel, C.G.2
Wieand, H.S.3
O'Connell, M.J.4
Poon, M.A.5
Krook, J.E.6
Mailliard, J.A.7
Tschetter, L.K.8
-
2
-
-
0027198871
-
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
-
Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818
-
(1993)
Cancer
, vol.71
, pp. 3813-3818
-
-
Kim, N.K.1
Park, Y.S.2
Heo, D.S.3
Suh, C.4
Kim, S.Y.5
Park, K.C.6
Kang, Y.K.7
Shin, D.B.8
Kim, H.T.9
Kim, H.J.10
-
3
-
-
18744373000
-
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
-
Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54-59
-
(2003)
J Clin Oncol
, vol.21
, pp. 54-59
-
-
Ohtsu, A.1
Shimada, Y.2
Shirao, K.3
Boku, N.4
Hyodo, I.5
Saito, H.6
Yamamichi, N.7
Miyata, Y.8
Ikeda, N.9
Yamamoto, S.10
Fukuda, H.11
Yoshida, S.12
-
4
-
-
18544367472
-
Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
-
Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 2005; 8: 95-102
-
(2005)
Gastric Cancer
, vol.8
, pp. 95-102
-
-
Ohtsu, A.1
-
5
-
-
0023280232
-
Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors
-
Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors. J Pharmacobiodyn 1987; 10: 148-151
-
(1987)
J Pharmacobiodyn
, vol.10
, pp. 148-151
-
-
Kunimoto, T.1
Nitta, K.2
Tanaka, T.3
Uehara, N.4
Baba, H.5
Takeuchi, M.6
Yokokura, T.7
Sawada, S.8
Miyasaka, T.9
Mutai, M.10
-
6
-
-
0028276113
-
Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer
-
CPT-11 Gastrointestinal Cancer Study Group
-
Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033-1038
-
(1994)
Gan To Kagaku Ryoho
, vol.21
, pp. 1033-1038
-
-
Futatsuki, K.1
Wakui, A.2
Nakao, I.3
Sakata, Y.4
Kambe, M.5
Shimada, Y.6
Yoshino, M.7
Taguchi, T.8
Ogawa, N.9
-
7
-
-
0031055829
-
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
-
Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921-927
-
(1997)
J Clin Oncol
, vol.15
, pp. 921-927
-
-
Shirao, K.1
Shimada, Y.2
Kondo, H.3
Saito, D.4
Yamao, T.5
Ono, H.6
Yokoyama, T.7
Fukuda, H.8
Oka, M.9
Watanabe, Y.10
Ohtsu, A.11
Boku, N.12
Fujii, T.13
Oda, Y.14
Muro, K.15
Yoshida, S.16
-
8
-
-
0032919992
-
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
-
Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323
-
(1999)
J Clin Oncol
, vol.17
, pp. 319-323
-
-
Boku, N.1
Ohtsu, A.2
Shimada, Y.3
Shirao, K.4
Seki, S.5
Saito, H.6
Sakata, Y.7
Hyodo, I.8
-
9
-
-
0036468440
-
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study
-
Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641-646
-
(2002)
Cancer
, vol.94
, pp. 641-646
-
-
Ajani, J.A.1
Baker, J.2
Pisters, P.W.3
Ho, L.4
Mansfield, P.F.5
Feig, B.W.6
Charnsangavej, C.7
-
10
-
-
0037256399
-
Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer
-
Fujitani K, Tsujinaka T, Hirao M. Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer. Oncology 2003; 64: 111-115
-
(2003)
Oncology
, vol.64
, pp. 111-115
-
-
Fujitani, K.1
Tsujinaka, T.2
Hirao, M.3
-
11
-
-
0020594425
-
Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer
-
Lacave AJ, Izarzugaza I, Anton Aparicio LM, Valle Pereda M, Gracia Marco JM, Buesa JM. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 1983; 6: 35-38
-
(1983)
Am J Clin Oncol
, vol.6
, pp. 35-38
-
-
Lacave, A.J.1
Izarzugaza, I.2
Anton Aparicio, L.M.3
Valle Pereda, M.4
Gracia Marco, J.M.5
Buesa, J.M.6
-
12
-
-
0027140524
-
Phase I and pharmacokinetic trial of weekly CPT-11
-
Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-2204
-
(1993)
J Clin Oncol
, vol.11
, pp. 2194-2204
-
-
Rothenberg, M.L.1
Kuhn, J.G.2
Burris III, H.A.3
Nelson, J.4
Eckardt, J.R.5
Tristan-Morales, M.6
Hilsenbeck, S.G.7
Weiss, G.R.8
Smith, L.S.9
Rodriguez, G.I.10
-
13
-
-
0027933519
-
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
-
de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-4354
-
(1994)
Cancer Res
, vol.54
, pp. 4347-4354
-
-
de Forni, M.1
Bugat, R.2
Chabot, G.G.3
Culine, S.4
Extra, J.M.5
Gouyette, A.6
Madelaine, I.7
Marty, M.E.8
Mathieu-Boue, A.9
-
14
-
-
0028158012
-
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
-
Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock MK, Donehower RC. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-436
-
(1994)
Cancer Res
, vol.54
, pp. 427-436
-
-
Rowinsky, E.K.1
Grochow, L.B.2
Ettinger, D.S.3
Sartorius, S.E.4
Lubejko, B.G.5
Chen, T.L.6
Rock, M.K.7
Donehower, R.C.8
-
15
-
-
0028854897
-
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
-
Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-221
-
(1995)
J Clin Oncol
, vol.13
, pp. 210-221
-
-
Abigerges, D.1
Chabot, G.G.2
Armand, J.P.3
Herait, P.4
Gouyette, A.5
Gandia, D.6
-
16
-
-
0028843263
-
Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11
-
Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995; 86: 111-116
-
(1995)
Jpn J Cancer Res
, vol.86
, pp. 111-116
-
-
Sasaki, Y.1
Yoshida, Y.2
Sudoh, K.3
Hakusui, H.4
Fujii, H.5
Ohtsu, T.6
Wakita, H.7
Igarashi, T.8
Itoh, K.9
-
17
-
-
0025851286
-
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
-
Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-1168
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 1164-1168
-
-
Negoro, S.1
Fukuoka, M.2
Masuda, N.3
Takada, M.4
Kusunoki, Y.5
Matsui, K.6
Takifuji, N.7
Kudoh, S.8
Niitani, H.9
Taguchi, T.10
-
18
-
-
0030068657
-
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
-
Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 1996; 56: 789-793
-
(1996)
Cancer Res
, vol.56
, pp. 789-793
-
-
Fukuda, M.1
Nishio, K.2
Kanzawa, F.3
Ogasawara, H.4
Ishida, T.5
Arioka, H.6
Bojanowski, K.7
Oka, M.8
Saijo, N.9
-
19
-
-
0028863688
-
In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve
-
Kobayashi K, Kudoh S, Takemoto T, Hino M, Hayashihara K, Nakahiro K, Ando M, Niitani H. In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve. J Cancer Res Clin Oncol 1995; 121: 715-720
-
(1995)
J Cancer Res Clin Oncol
, vol.121
, pp. 715-720
-
-
Kobayashi, K.1
Kudoh, S.2
Takemoto, T.3
Hino, M.4
Hayashihara, K.5
Nakahiro, K.6
Ando, M.7
Niitani, H.8
-
20
-
-
0029948891
-
Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions
-
Kurihara N, Kubota T, Hoshiya Y, Otani Y, Ando N, Kumai K, Kitajima M. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J Surg Oncol 1996; 62: 135-138
-
(1996)
J Surg Oncol
, vol.62
, pp. 135-138
-
-
Kurihara, N.1
Kubota, T.2
Hoshiya, Y.3
Otani, Y.4
Ando, N.5
Kumai, K.6
Kitajima, M.7
-
21
-
-
0030038773
-
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
-
Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G, Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996; 73: 1569-1575
-
(1996)
Br J Cancer
, vol.73
, pp. 1569-1575
-
-
Schellens, J.H.1
Ma, J.2
Planting, A.S.3
van der Burg, M.E.4
van Meerten, E.5
de Boer-Dennert, M.6
Schmitz, P.I.7
Stoter, G.8
Verweij, J.9
-
22
-
-
0032015824
-
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: A comparative study of three different schedules of cisplatin administration
-
Ikeda K, Terashima M, Kawamura H, Takiyama I, Koeda K, Takagane A, Sato N, Ishida K, Iwaya T, Maesawa C, Yoshinari H, Saito K. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998; 28: 168-175
-
(1998)
Jpn J Clin Oncol
, vol.28
, pp. 168-175
-
-
Ikeda, K.1
Terashima, M.2
Kawamura, H.3
Takiyama, I.4
Koeda, K.5
Takagane, A.6
Sato, N.7
Ishida, K.8
Iwaya, T.9
Maesawa, C.10
Yoshinari, H.11
Saito, K.12
-
23
-
-
0035035706
-
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer
-
Sato A, Kurihara M, Matsukawa M, Shimada K, Yamazaki T, Nakamachi M, Koda T. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol 2001; 47: 380-384
-
(2001)
Cancer Chemother Pharmacol
, vol.47
, pp. 380-384
-
-
Sato, A.1
Kurihara, M.2
Matsukawa, M.3
Shimada, K.4
Yamazaki, T.5
Nakamachi, M.6
Koda, T.7
-
24
-
-
0035289195
-
Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma
-
Ajani JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park) 2001; 15: 52-54
-
(2001)
Oncology (Williston Park)
, vol.15
, pp. 52-54
-
-
Ajani, J.A.1
Baker, J.2
Pisters, P.W.3
Ho, L.4
Feig, B.5
Mansfield, P.F.6
-
25
-
-
0642283904
-
Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil
-
Shimada S, Yagi Y, Kuramoto M, Aoki N, Ogawa M. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil. Oncol Rep 2003; 10: 687-691
-
(2003)
Oncol Rep
, vol.10
, pp. 687-691
-
-
Shimada, S.1
Yagi, Y.2
Kuramoto, M.3
Aoki, N.4
Ogawa, M.5
|